2023-05-08 07:33:29 ET
- BioRestorative Therapies ( NASDAQ: BRTX ) said New York State's largest health care provider Northwell Health will participate in the company's ongoing phase 2 trial of BRTX-100 to treat chronic lumbar disc disease (cLDD).
- The trial will evaluate a single injectable dose of BRTX-100. A total of up to 99 patients will receive either BRTX-100 or a control at up to 15 sites in the U.S.
- "We are delighted to enter into such an agreement with Northwell and their world class team of non-surgical and surgical spine clinicians and researchers across the disciplines. We hope to identify other areas where our two organizations can work closely with one another," said BioRestorative CEO Lance Alstodt.
- Lumbar disk disease causes lower back and leg pain due to wear and tear on a spinal disc.
- BRTX +2.27% to $4.50 premarket May 8
For further details see:
BioRestorative, Northwell Health team up for trial of lumbar disc disease drug